Editas Medicine Inc

Editas Medicine Inc

  • Price (USD)7.41
  • Today's Change0.300 / 4.22%
  • Shares traded1.41m
  • 1 Year change-63.75%
  • Beta1.9004
Data delayed at least 15 minutes, as of Mar 29 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).

  • Revenue in USD (TTM)19.71m
  • Net income in USD-220.43m
  • Incorporated2013
  • Employees226.00
  • Location
    Editas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
  • Phone+1 (617) 401-9000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.editasmedicine.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
2Seventy Bio Inc91.50m-254.15m462.25m425.00--1.13--5.05-7.58-7.582.578.190.1292--4.82215,284.70-35.89---41.05--81.88---277.78------0.00--67.81--13.02------
Evolus Inc148.62m-74.41m463.14m215.00--24.97--3.12-1.33-1.332.650.32880.68265.428.01691,237.20-34.18-40.34-44.92-65.1262.40---50.07-123.951.76-6.640.7953--49.10---58.97------
Janux Therapeutics Inc8.61m-63.06m470.62m60.00--1.46--54.65-1.52-1.520.20777.710.0232----143,533.30-16.96---17.65-------732.22------0.00--136.79---93.01------
Aerovate Therapeutics Inc0.00-44.73m471.68m33.00--3.38-----1.85-1.850.005.680.00----0.00-26.95---27.92--------------0.00-------135.41------
Arbutus Biopharma Corp39.02m-69.46m487.71m96.00--3.45--12.50-0.4589-0.45890.25850.86920.1951--34.67406,447.90-34.74-47.15-39.04-50.77-----178.01-610.12----0.00--255.1129.5321.42---41.17--
Editas Medicine Inc19.71m-220.43m490.38m226.00--1.36--24.88-3.21-3.210.28715.240.0331--7.2887,216.81-36.99-29.45-40.64-32.55-----1,118.32-409.97----0.00---22.837.50-14.51--14.87--
Agenus Inc98.03m-220.29m492.12m533.00------5.02-0.778-0.7780.348-0.20050.2229--46.03183,911.80-52.45-57.35-89.79-110.5489.22---235.30-107.06---2.95-----66.8517.98-812.65--76.24--
Entrada Therapeutics Inc0.00-94.62m492.84m130.00--2.20-----3.02-
Cerus Corporation188.32m-42.78m495.55m309.00--7.33--2.63-0.2424-0.24241.070.38070.82672.696.32609,433.70-18.80-30.22-33.19-45.1660.2061.29-22.74-45.241.21-5.230.5045--18.0529.6921.32--41.47--
iTeos Therapeutics Inc267.63m96.65m497.94m125.005.480.75075.111.862.552.557.0918.570.3264--36.852,141,040.0011.79--14.94------36.11------0.00---22.38---54.95------
Coherus Biosciences Inc211.04m-291.75m511.09m359.00------2.42-3.76-3.762.72-1.740.36381.831.81587,860.80-50.29-24.08-68.15-31.3066.79---138.24-41.342.47-7.911.41---35.37166.98-1.62---14.92--
Terns Pharmaceuticals Inc1.00m-58.77m512.73m41.00--2.19--512.73-2.10-2.100.0354.880.0054----24,390.24-31.56---32.82-------5,877.10------0.00-------70.88------
BioXcel Therapeutics Inc375.00k-165.76m513.47m183.00--6.49--1,369.25-5.92-5.920.01342.730.0017----2,049.18-74.45-63.32-83.77-69.7594.67---44,201.33-108,558.706.11-28.080.5479-------55.01------
Zymeworks Inc412.48m124.34m516.81m291.004.591.063.931.251.761.766.327.640.7949--16.831,417,464.0023.96-23.3128.57-28.03----30.14-80.27----0.0003--1,446.0351.45158.69--33.28--
Alector Inc133.62m-130.06m517.26m273.00--2.41--3.87-1.58-1.621.622.590.1668--26.78489,439.60-16.23-20.21-19.00-23.73-----97.33-125.21----0.00---35.48104.51-258.00--38.74--
Fate Therapeutics Inc96.30m-281.72m517.31m551.00--1.06--5.37-2.91-2.910.99464.970.1184--4.08174,773.10-34.63-33.76-39.36-38.16-----292.55-418.09----0.00--72.4487.95-32.79--83.17--
Data as of Mar 29 2023. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD

Institutional shareholders

47.37%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 31 Dec 20229.22m13.41%
The Vanguard Group, Inc.as of 31 Dec 20226.75m9.82%
BlackRock Fund Advisorsas of 31 Dec 20225.68m8.27%
Millennium Management LLCas of 31 Dec 20222.14m3.12%
Woodline Partners LPas of 31 Dec 20222.08m3.02%
Dimensional Fund Advisors LPas of 31 Dec 20221.65m2.40%
PFM Health Sciences LPas of 31 Dec 20221.47m2.13%
Geode Capital Management LLCas of 31 Dec 20221.38m2.01%
Capital Research & Management Co. (World Investors)as of 31 Dec 20221.10m1.60%
Two Sigma Advisers LPas of 31 Dec 20221.10m1.59%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.